How do you incorporate CAR-T cell therapy in the second line setting for DLBCL patients who are eligible for consolidative autologous transplant?
Does the result of their salvage chemotherapy and whether PR or CR is acheived affect your decision?
Answer from: Medical Oncologist at Academic Institution
The role of sequential therapy including CARs vs high dose chemotherapy + ASCT post primary induction failure/relapse in large cell lymphoma is a matter of active research. Given the present FDA indication of CARs is in relapsed/refractory large cell lymphoma after failure of at least 2 lines ...
Sign in or Register to read more